Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab vs placebo in moderate to severe chronic plaque-type psoriasis
2010-023512-13Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Secukinumab with Placebo (2 arms). Primary endpoints: PASI response at 12 weeks and IGA response at 12 weeks. Started Apr 2011; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2010-023512-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023512-13.